On September 3, Moderna, Inc. fell 3.49% in regular trading, trading at approximately $146.77 per share, with turnover of $217 million. The decline was driven by a rating downgrade from Rothschild & Co Redburn combined with persistent mechanical selling pressure tied to convertible debt arbitrage.
Rothschild & Co Redburn downgraded Moderna, Inc. from Neutral to Sell, adjusting its price target to $81 from $40 — still well below the current share price — making it the first major institution to issue an explicit bearish signal amid a recent wave of upgrades. According to FactSet, the stock currently carries a consensus Hold rating with a mean price target of $108. Meanwhile, the company recently completed pricing on a $2.6 billion zero-coupon convertible senior notes offering, upsized from an originally planned $2 billion. Arbitrage funds purchasing the convertible notes are required to short the common stock as a hedge, and this mechanical selling pressure has yet to be fully absorbed, continuing to weigh on the stock in the near term.
The downgrade and convertible-related overhang came despite a string of at least five recent upgrades from firms including Argus Research, Barclays, and JPMorgan, all citing the breakthrough Phase 3 results of Moderna's personalized mRNA melanoma cancer vaccine developed with Merck.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments